Digg It - Business

Increasing shareholder value is the most important driver for organi

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

sations in the modern business world. Shareholder value is built through g

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

owing profit and building confidence in the organisation, which moves share

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

prices upwards. Shareholders like this!

And the employees of

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

n organisation have a crucial part to play in both elements of this.

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

They contribute to sales by selling more, both to new and old cus

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

omers. They build the customer base by word of mouth from existing custome

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

s. New customers are pre-filtered because your existing customers tell the

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

exactly what you do, so more customer interactions are converted, with les

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

s wasted time. This means that your costs are kept down.

Your peo

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

le buy better because they build great relationships with suppliers - so th

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

y get the best deals. Both sides win, so the relationship blossoms.

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

Great people in your organisation work hard to keep costs low, because th

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

ey are enabled to do so. They have freedom to be creative. They get very

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

ocused on the 'Does it create value?' question and work together, wi

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

h the best results as their only goal.

With all this positive acti

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

ity, the organisation looks and feels strong to it's customers, suppliers a

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

nd shareholders. With this and a great profit performance, confidence grow

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

.

Shareholders enjoy great improvements in the value of the growth

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

in the price of the shares they hold and the dividends they receive.

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.diggit.org.ua/article/24730/diggit-Building-Shareholder-Value-Through-Your-People.html">Building Shareholder Value Through Your People</a>

BB link (for phorums):
[url=http://www.diggit.org.ua/article/24730/diggit-Building-Shareholder-Value-Through-Your-People.html]Building Shareholder Value Through Your People[/url]

Medical billing of enteral claims is a complex process. Many calculations must be done to accurately do this. In this installment covering the GE0 CMN, we cover fields 15 through 20.

To succeed, entrepreneurs must have many skills that allow them to conceive, launch and grow new products, services and/or companies. This article describes some of the most critical skills that an entrepreneur must possess.

Tags

Links

Digg It - Building Shareholder Value Through Your People

Related Articles: